CYP4F2 polymorphism as a genetic risk factor for major hemorrhagic complications in Chinese patients on warfarin therapy

被引：5

作者：

Wang, Hong-Juan ^{[1
]}

Ma, Cong ^{[1
]}

Yang, Jie ^{[1
]}

Xu, Qiang ^{[1
]}

Zhang, Yan ^{[1
]}

Gao, Lei ^{[1
]}

Xu, Bin ^{[1
]}

Zhang, Yu-Xiao ^{[1
]}

Li, Yang ^{[1
]}

Yin, Tong ^{[1
]}

机构：

[1] Chinese Peoples Liberat Army, Inst Geriatr Cardiol, Gen Hosp, Beijing 100853, Peoples R China

来源：

JOURNAL OF GERIATRIC CARDIOLOGY | 2012年 / 9卷 / 02期

关键词：

CYP4F2; Genetic risk factor; Warfarin; Complications; CYP2C9; ANTICOAGULATION; ASSOCIATION; VARIANT;

D O I：

10.3724/SP.J.1263.2012.04162

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：209 / 210

页数：2

共 10 条

[1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[2] CYP4F2 genetic variant alters required warfarin dose [J].

Caldwell, Michael D. ;

Awad, Tarif ;

Johnson, Julie A. ;

Gage, Brian F. ;

Falkowski, Mat ;

Gardina, Paul ;

Hubbard, Jason ;

Turpaz, Yaron ;

Langaee, Taimour Y. ;

Eby, Charles ;

King, Cristi R. ;

Brower, Amy ;

Schmelzer, John R. ;

Glurich, Ingrid ;

Vidaillet, Humberto J. ;

Yale, Steven H. ;

Zhang, Kai Qi ;

Berg, Richard L. ;

Burmester, James K. .

BLOOD, 2008, 111 (08) :4106-4112

[3] RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY [J].

FIHN, SD ;

MCDONELL, M ;

MARTIN, D ;

HENIKOFF, J ;

VERMES, D ;

KENT, D ;

WHITE, RH .

ANNALS OF INTERNAL MEDICINE, 1993, 118 (07) :511-520

[4] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].

Higashi, MK ;

Veenstra, DL ;

Kondo, LML ;

Wittkowsky, AK ;

Srinouanprachanh, SL ;

Farin, FM ;

Rettie, AE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698

[5] Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin [J].

Limdi, Na ;

McGwin, G. ;

Goldstein, J. A. ;

Beasley, T. M. ;

Arnett, D. K. ;

Adler, B. K. ;

Baird, M. F. ;

Acton, R. T. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :312-321

[6] Several-fold increase in risk of overanticoagulation by CYP2C9 mutations [J].

Lindh, JD ;

Lundgren, S ;

Holm, L ;

Alfredsson, L ;

Rane, A .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (05) :540-550

[7] CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant [J].

McDonald, Matthew G. ;

Rieder, Mark J. ;

Nakano, Mariko ;

Hsia, Clara K. ;

Rettie, Allan E. .

MOLECULAR PHARMACOLOGY, 2009, 75 (06) :1337-1346

[8] Genetic determinants of response to warfarin during initial anticoagulation [J].

Schwarz, Ute I. ;

Ritchie, Marylyn D. ;

Bradford, Yuki ;

Li, Chun ;

Dudek, Scott M. ;

Frye-Anderson, Amy ;

Kim, Richard B. ;

Roden, Dan M. ;

Stein, C. Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (10) :999-1008

[9] A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose [J].

Takeuchi, Fumihiko ;

McGinnis, Ralph ;

Bourgeois, Stephane ;

Barnes, Chris ;

Eriksson, Niclas ;

Soranzo, Nicole ;

Whittaker, Pamela ;

Ranganath, Venkatesh ;

Kumanduri, Vasudev ;

McLaren, William ;

Holm, Lennart ;

Lindh, Jonatan ;

Rane, Anders ;

Wadelius, Mia ;

Deloukas, Panos .

PLOS GENETICS, 2009, 5 (03)

[10] The largest prospective warfarin-treated cohort supports genetic forecasting [J].

Wadelius, Mia ;

Chen, Leslie Y. ;

Lindh, Jonatan D. ;

Eriksson, Niclas ;

Ghori, Mohammed J. R. ;

Bumpstead, Suzannah ;

Holm, Lennart ;

McGinnis, Ralph ;

Rane, Anders ;

Deloukas, Panos .

BLOOD, 2009, 113 (04) :784-792

← 1 →